These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 19902363)
1. Comparison of two pharmacodynamic transduction models for the analysis of tumor therapeutic responses in model systems. Yang J; Mager DE; Straubinger RM AAPS J; 2010 Mar; 12(1):1-10. PubMed ID: 19902363 [TBL] [Abstract][Full Text] [Related]
2. Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. Simeoni M; Magni P; Cammia C; De Nicolao G; Croci V; Pesenti E; Germani M; Poggesi I; Rocchetti M Cancer Res; 2004 Feb; 64(3):1094-101. PubMed ID: 14871843 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo. O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895 [TBL] [Abstract][Full Text] [Related]
4. Lifespan based pharmacokinetic-pharmacodynamic model of tumor growth inhibition by anticancer therapeutics. Mo G; Gibbons F; Schroeder P; Krzyzanski W PLoS One; 2014; 9(10):e109747. PubMed ID: 25333487 [TBL] [Abstract][Full Text] [Related]
5. Superparamagnetic Iron Oxide Nanorod Carriers for Paclitaxel Delivery in the Treatment and Imaging of Colon Cancer in Mice. Dehvari K; Chen Y; Tsai YH; Tseng SH; Lin KS J Biomed Nanotechnol; 2016 Sep; 12(9):1734-45. PubMed ID: 29345885 [TBL] [Abstract][Full Text] [Related]
6. Anticancer efficacy and toxicokinetics of a novel paclitaxel-clofazimine nanoparticulate co-formulation. Koot D; Cromarty D Drug Deliv Transl Res; 2015 Jun; 5(3):257-67. PubMed ID: 25795051 [TBL] [Abstract][Full Text] [Related]
7. Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models. Wang S; Guo P; Wang X; Zhou Q; Gallo JM Mol Cancer Ther; 2008 Feb; 7(2):407-17. PubMed ID: 18281523 [TBL] [Abstract][Full Text] [Related]
8. Chemotherapeutic dosing implicated by pharmacodynamic modeling of in vitro cytotoxic data: a case study of paclitaxel. He H; Cao Y J Pharmacokinet Pharmacodyn; 2017 Oct; 44(5):491-501. PubMed ID: 28861682 [TBL] [Abstract][Full Text] [Related]
9. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Lee FY; Borzilleri R; Fairchild CR; Kim SH; Long BH; Reventos-Suarez C; Vite GD; Rose WC; Kramer RA Clin Cancer Res; 2001 May; 7(5):1429-37. PubMed ID: 11350914 [TBL] [Abstract][Full Text] [Related]
10. PBPK modeling-based optimization of site-specific chemo-photodynamic therapy with far-red light-activatable paclitaxel prodrug. Li M; Nguyen L; Subramaniyan B; Bio M; Peer CJ; Kindrick J; Figg WD; Woo S; You Y J Control Release; 2019 Aug; 308():86-97. PubMed ID: 31299262 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic and pharmacodynamic analysis of neutropenia following nab-paclitaxel administration in Japanese patients with metastatic solid cancer. Tsushima T; Kasai H; Tanigawara Y Cancer Chemother Pharmacol; 2020 Oct; 86(4):487-495. PubMed ID: 32930844 [TBL] [Abstract][Full Text] [Related]
12. The Effect of Phase Transition Temperature on Therapeutic Efficacy of Liposomal Bortezomib. Korani M; Nikoofal-Sahlabadi S; Nikpoor AR; Ghaffari S; Attar H; Mashreghi M; Jaafari MR Anticancer Agents Med Chem; 2020; 20(6):700-708. PubMed ID: 31893998 [TBL] [Abstract][Full Text] [Related]
13. Preclinical PK/PD model for the combinatorial use of dexamethasone and sulpiride in the treatment of breast cancer. Yao QY; Li J; Chen R; Yao Y; Xue JS; Chen WJ; Lu W; Zhou TY Acta Pharmacol Sin; 2019 Dec; 40(12):1596-1602. PubMed ID: 31165782 [TBL] [Abstract][Full Text] [Related]
14. Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance. Zhang L; Beal SL; Sheiner LB J Pharmacokinet Pharmacodyn; 2003 Dec; 30(6):387-404. PubMed ID: 15000421 [TBL] [Abstract][Full Text] [Related]
15. A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis. Pillai G; Gieschke R; Goggin T; Jacqmin P; Schimmer RC; Steimer JL Br J Clin Pharmacol; 2004 Dec; 58(6):618-31. PubMed ID: 15563360 [TBL] [Abstract][Full Text] [Related]